Results 221 to 230 of about 107,795 (308)

The Real World Impact of Immunoglobulin Replacement Therapy on Severe Bacterial Infection for Patients With Hypogammaglobulinemia Secondary to Hematologic Malignancies: A Japanese Claims Database Study

eJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Objectives The understanding of usefulness of immunoglobulin replacement therapy (IgRT) for hypogammaglobulinemia (HGG) in patients with hematologic malignancies (HM) has changed over time. This is mainly caused by the introduction of new treatment, such as B‐cell targeted agents.
Keichiro Mihara, Takakazu Kawase, Takahiko Miyama, Katsuhiko Iwasaki, Ayako Shoji, Masayuki Matsumaru   +5 more
wiley   +1 more source

The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. [PDF]

Am J Hematol
DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Illés Á, Kim I, Ivanov V, Ku G, Miller CL, Zhang M, Tatsch F, Potluri J, Schmidt X, Récher C.   +14 more
europepmc   +1 more source

Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors.

, 1994
C Y Wang, Alexander G. Bassuk, Lawrence Boise, Craig B. Thompson, R Bravo, Jeffrey M. Leiden   +5 more
openalex   +1 more source

Maternal Immune Activation During Pregnancy and Obstetric Outcomes: A Population‐Based Cohort Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 132, Issue 9, Page 1307-1318, August 2025.
ABSTRACT Objective Maternal immune activation has been proposed as a mechanism for adverse pregnancy outcomes, yet the mechanisms and effects of timing remain unclear. Immune disruption in early gestation may be particularly detrimental as this is an important period for placental development, which has been associated with the pathology of adverse ...
Frederieke A. J. Gigase, Myrthe M. G. B. M. Boekhorst, Anna Suleri, Anna‐Sophie Rommel, Michael Breen, Ryan L. Muetzel, Manon H. J. Hillegers, Michal A. Elovitz, Eric A. P. Steegers, Lot D. De Witte, Veerle Bergink   +10 more
wiley   +1 more source

The granulocyte colony-stimulating factor produced during Streptococcus suis infection controls neutrophil recruitment in the blood without affecting bacterial clearance. [PDF]

Front Immunol
Bleuzé M, Lehoux M, Auger JP, Gottschalk M, Segura M.   +4 more
europepmc   +1 more source

The Optimal Timing and Duration of Daily G‐CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy

Asia-Pacific Journal of Clinical Oncology, Volume 21, Issue 4, Page 383-391, August 2025.
The study aimed to determine the optimal timing and duration of filgrastim administration for the primary prevention of febrile neutropenia (FN) in breast cancer patients undergoing adjuvant TAC chemotherapy. Our findings suggest that initiating daily filgrastim from Day 2 and continuing for 7 days optimizes toxicity reduction.
Zisun Kim, Sung Mo Hur, Jong Eun Lee, Sun Wook Han, Hae Il Jung, Sung Yong Kim, Jihyoun Lee, Cheol Wan Lim   +7 more
wiley   +1 more source

Daratumumab improved severe neutrophilia and paraneoplastic bone marrow fibrosis in granulocyte-colony stimulating factor-producing multiple myeloma. [PDF]

EJHaem
Sakamoto M, Shiroshita K, Fujita S, Kudo H, Abe R, Kohashi S, Shiozawa Y, Nakanishi K, Toyama T.   +8 more
europepmc   +1 more source

Neoadjuvant Chemotherapy With Chemoradiotherapy for Patients With Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma—Retrospective Review From a Tertiary Care Hospital

Asia-Pacific Journal of Clinical Oncology, Volume 21, Issue 4, Page 392-398, August 2025.
A single‐centre retrospectively analyzed 37 BRPC/LAPC patients receiving neoadjuvant chemotherapy ± chemoradiotherapy. Surgical resection was feasible in 62% of patients, with 38% of patients achieving R0 resections. The median overall survival was 21 months, and disease‐free survival was 12.7 months.
Avtaj Nerwal, Desmond Yip, Sivakumar Gananadha, Amy Shorthouse, Belinda Lee, Ankit Jain   +5 more
wiley   +1 more source

Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia. [PDF]

Chin Med J (Engl)
Cao X, Zhang M, Guo R, Zhang X, Sun R, Xiao X, Bai X, Lyu C, Pu Y, Meng J, Zhang H, Zhu H, Liu P, Wang Z, Zhang Y, Lu W, Lyu H, Zhao M.   +17 more
europepmc   +1 more source